Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR 1,580.00
+3.70 (0.23%)
Jul 31, 2026, 3:30 PM IST
Aurobindo Pharma Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 336,531 | 336,531 | 317,237 | 290,019 | 248,554 | 234,555 |
Revenue Growth | 6.08% | 6.08% | 9.38% | 16.68% | 5.97% | -5.33% |
Gross Profit Gross Profit Growth | 201,647 | 201,647 | 182,399 | 160,162 | 132,137 | 130,056 |
Operating Income Operating Income Growth | 50,776 | 50,776 | 50,324 | 43,915 | 25,119 | 33,064 |
Net Income Net Income Growth | 35,048 | 35,048 | 34,859 | 31,730 | 19,275 | 26,482 |
Earnings Per Share EPS Growth | 60.34 | 60.34 | 59.81 | 54.15 | 32.90 | 45.19 |
EPS Growth | 0.89% | 0.89% | 10.44% | 64.62% | -27.21% | -50.37% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 36,014 | 34,020 | 27,482 | 26,700 |
USA USA Growth | 144,785 | 139,804 | 112,421 | 105,208 |
Europe Europe Growth | 92,361 | 75,633 | 72,430 | 78,813 |
Rest of the World Rest of the World Growth | 44,078 | 40,562 | 36,222 | 23,835 |
Total Total Growth | 317,237 | 290,019 | 248,554 | 234,555 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 106,175 | 106,175 | 82,013 | 63,264 | 62,327 | 45,663 |
Total Debt Total Debt Growth | 80,728 | 80,728 | 82,629 | 66,476 | 52,862 | 28,513 |
Net Cash (Debt) Net Cash Growth | 25,447 | 25,447 | -615.9 | -3,213 | 9,465 | 17,150 |
Net Cash Growth | - | - | - | - | -44.81% | 486.55% |
Net Cash Per Share Net Cash Per Share Growth | 43.81 | 43.81 | -1.06 | -5.48 | 16.15 | 29.27 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 55,264 | 55,264 | 39,246 | 24,345 | 23,868 | 50,165 |
Capital Expenditures CapEx Growth | -26,858 | -26,858 | -19,679 | -27,803 | -24,038 | -20,529 |
Free Cash Flow Free Cash Flow Growth | 28,406 | 28,406 | 19,568 | -3,458 | -170.5 | 29,636 |
Free Cash Flow Growth | 45.17% | 45.17% | - | - | - | 56.71% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 59.92% | 59.92% | 57.50% | 55.23% | 53.16% | 55.45% |
Operating Margin | 15.09% | 15.09% | 15.86% | 15.14% | 10.11% | 14.10% |
Pretax Margin | 15.19% | 15.19% | 15.97% | 15.10% | 10.51% | 14.38% |
Profit Margin | 10.41% | 10.41% | 10.99% | 10.94% | 7.75% | 11.29% |
FCF Margin | 8.44% | 8.44% | 6.17% | -1.19% | -0.07% | 12.63% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 8.000 | - | - | 4.500 | 3.000 | 9.000 |
Dividend Per Share Growth | 0% | - | - | 50.00% | -66.67% | 125.00% |
Dividend Yield | 0.51% | - | - | 0.41% | 0.58% | 1.38% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 26.19 | 21.62 | 19.34 | 20.11 | 15.75 | 14.79 |
Forward PE | 20.36 | 18.02 | 15.91 | 17.77 | 12.19 | 12.83 |
P/FCF Ratio | 32.01 | 26.67 | 34.45 | - | - | 13.22 |
PS Ratio | 2.70 | 2.25 | 2.13 | 2.20 | 1.22 | 1.67 |